Literature DB >> 8831598

Abnormal lipoprotein pattern in patients with Alagille syndrome depends on Icterus severity.

A Davit-Spraul1, M L Pourci, V Atger, M Cambillau, M Hadchouel, N Moatti, A Legrand.   

Abstract

BACKGROUND & AIMS: Children with Alagille syndrome have lipid abnormalities that differ according to the severity of icteric periods. The lipoprotein profiles of 22 patients with Alagille syndrome were determined and the findings were compared with the severity of jaundice.
METHODS: Plasma lipids and apolipoproteins (apos), isolated lipoprotein composition, and lecithin/ cholesterol acyltransferase (LCAT) activity were analyzed in patients. Patients were classified into two groups according to their bilirubin levels; patients in group I had total bilirubin levels of > 100 mumol/L, and patients in group II had total bilirubin levels of < 100 mumol/L.
RESULTS: In patients from group II, hypercholesterolemia was associated with increased levels of high-density lipoprotein and high concentrations of apoAI and apoAII; in a few cases, an abnormal lipoprotein with a slow alpha migration was observed. In contrast, in patients from group I, the levels of high-density lipoprotein cholesterol and apoAI and apoAII were very low, and the abnormal lipoprotein X was in many cases responsible for hypercholesterolemia. In group I, the decreased LCAT activity was consistent with the very high level of unesterified cholesterol and the emergence of lipoprotein X. In both groups of patients, the levels of apoE, apoCII, and apoCIII were high, and all the lipoprotein fractions were enriched in phospholipids.
CONCLUSIONS: The variations of LCAT activity caused by the degree of jaundice in patients with Alagille syndrome are implicated in the abnormal lipid profiles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831598     DOI: 10.1016/s0016-5085(96)70071-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

Review 1.  Alagille syndrome.

Authors:  Michelle Hadchouel
Journal:  Indian J Pediatr       Date:  2002-09       Impact factor: 1.967

2.  Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites.

Authors:  Junichiro Sonoda; Ling Wa Chong; Michael Downes; Grant D Barish; Sally Coulter; Christopher Liddle; Chih-Hao Lee; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-25       Impact factor: 11.205

3.  Atherosclerosis causing recurrent catastrophic aortopulmonary shunt dehiscence in a patient with Alagille syndrome.

Authors:  L May; F L Hanley; A J Connolly; S Reddy
Journal:  Pediatr Cardiol       Date:  2012-08-26       Impact factor: 1.655

4.  A Case of Infantile Alagille Syndrome With Severe Dyslipidemia: New Insight into Lipid Metabolism and Therapeutics.

Authors:  Hisakazu Nakajima; Yusuke Tsuma; Shota Fukuhara; Kazuki Kodo
Journal:  J Endocr Soc       Date:  2022-01-18

5.  Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis.

Authors:  Rossella Colantuono; Chiara Pavanello; Andrea Pietrobattista; Marta Turri; Paola Francalanci; Marco Spada; Pietro Vajro; Laura Calabresi; Claudia Mandato
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

6.  Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion.

Authors:  Karan M Emerick; Marc S Elias; Hector Melin-Aldana; Sandra Strautnieks; Richard J Thompson; Laura N Bull; A s Knisely; Peter F Whitington; Richard M Green
Journal:  BMC Gastroenterol       Date:  2008-10-20       Impact factor: 3.067

7.  LCAT protects against Lipoprotein-X formation in a murine model of drug-induced intrahepatic cholestasis.

Authors:  Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley
Journal:  Pharmacol Res Perspect       Date:  2019-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.